NASDAQ:CRGX CARGO Therapeutics (CRGX) Stock Price, News & Analysis $12.39 +0.39 (+3.25%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About CARGO Therapeutics Stock (NASDAQ:CRGX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CARGO Therapeutics alerts:Sign Up Key Stats Today's Range$11.91▼$12.9050-Day Range$11.18▼$21.1452-Week Range$10.91▼$33.92Volume245,401 shsAverage Volume252,993 shsMarket Capitalization$570.31 millionP/E RatioN/ADividend YieldN/APrice Target$31.80Consensus RatingBuy Company OverviewCARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.Read More… CARGO Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks35th Percentile Overall ScoreCRGX MarketRank™: CARGO Therapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 780th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCARGO Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCARGO Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about CARGO Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CARGO Therapeutics are expected to decrease in the coming year, from ($3.73) to ($4.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CARGO Therapeutics is -2.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CARGO Therapeutics is -2.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCARGO Therapeutics has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CARGO Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.87% of the float of CARGO Therapeutics has been sold short.Short Interest Ratio / Days to CoverCARGO Therapeutics has a short interest ratio ("days to cover") of 27.3, which indicates bearish sentiment.Change versus previous monthShort interest in CARGO Therapeutics has recently increased by 7.08%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCARGO Therapeutics does not currently pay a dividend.Dividend GrowthCARGO Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted18.87% of the float of CARGO Therapeutics has been sold short.Short Interest Ratio / Days to CoverCARGO Therapeutics has a short interest ratio ("days to cover") of 27.3, which indicates bearish sentiment.Change versus previous monthShort interest in CARGO Therapeutics has recently increased by 7.08%, indicating that investor sentiment is decreasing significantly. News and Social Media3.1 / 5News Sentiment0.55 News SentimentCARGO Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for CARGO Therapeutics this week, compared to 2 articles on an average week.Search Interest3 people have searched for CRGX on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CARGO Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.38% of the stock of CARGO Therapeutics is held by insiders.Percentage Held by Institutions93.16% of the stock of CARGO Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CARGO Therapeutics' insider trading history. Receive CRGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CARGO Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CRGX Stock News HeadlinesWhat is William Blair's Forecast for CRGX Q1 Earnings?January 17 at 2:10 AM | americanbankingnews.comWilliam Blair Keeps Their Buy Rating on CARGO Therapeutics, Inc. (CRGX)January 15, 2025 | markets.businessinsider.comVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.January 20, 2025 | Porter & Company (Ad)CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025January 10, 2025 | finance.yahoo.comCargo Therapeutics (NASDAQ:CRGX) Stock Quotes, Forecast and News SummaryDecember 31, 2024 | benzinga.comCARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceDecember 17, 2024 | globenewswire.comCARGO Therapeutics, Inc. (CRGX) Receives a Buy from Truist FinancialDecember 10, 2024 | markets.businessinsider.comCARGO Therapeutics, Inc.: Buy Rating Backed by Promising CAR-T Developments and Positive Clinical DataDecember 9, 2024 | markets.businessinsider.comSee More Headlines CRGX Stock Analysis - Frequently Asked Questions How have CRGX shares performed this year? CARGO Therapeutics' stock was trading at $14.42 at the start of the year. Since then, CRGX stock has decreased by 14.1% and is now trading at $12.39. View the best growth stocks for 2025 here. How were CARGO Therapeutics' earnings last quarter? CARGO Therapeutics, Inc. (NASDAQ:CRGX) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.26. When did CARGO Therapeutics IPO? CARGO Therapeutics (CRGX) raised $281 million in an IPO on Friday, November 10th 2023. The company issued 18,750,000 shares at $15.00 per share. Who are CARGO Therapeutics' major shareholders? Top institutional shareholders of CARGO Therapeutics include Brooklyn Investment Group. Insiders that own company stock include Samsara Biocapital Gp, Llc, Perceptive Advisors Llc, Gina Chapman and Anup Radhakrishnan. View institutional ownership trends. How do I buy shares of CARGO Therapeutics? Shares of CRGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CARGO Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CARGO Therapeutics investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings11/12/2024Today1/20/2025Next Earnings (Estimated)3/20/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRGX Previous SymbolNASDAQ:CRGX CUSIPN/A CIK1966494 Webcargo-tx.com Phone650-379-6143FaxN/AEmployees116Year FoundedN/APrice Target and Rating Average Stock Price Target$31.80 High Stock Price Target$34.00 Low Stock Price Target$28.00 Potential Upside/Downside+156.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($4.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-98,150,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.16% Return on Assets-33.94% Debt Debt-to-Equity RatioN/A Current Ratio18.94 Quick Ratio18.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.84 per share Price / Book1.26Miscellaneous Outstanding Shares46,030,000Free Float45,393,000Market Cap$570.31 million OptionableN/A Beta2.50 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:CRGX) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CARGO Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CARGO Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.